24 Jan 2014, BioSpectrum Bureau , BioSpectrum
Singapore: US drug major Eli Lilly and Co has announced that it is looking at introducing more products in India to become one amongst the top 20 pharmaceutical companies in the country by the year 2020.
Lilly India announced that it is looking at introducing more innovation-based products across five therapeutic segments, including diabetes, over the next six years in the country.
Speaking at the launch of the insulin delivery pen - Humapen Savvio, Mr Edgard A Olaizola, Managing Director, Eli Lilly and Co India told PTI, "We are committed to India and it's our aim to be among the top twenty pharma companies in India by 2020."
The company is currently placed at the 47th position in terms of revenues among pharma companies in India.
Mr Olaizola added that the company would be laying maximum emphasis on its diabetes portfolio and would be introducing new products to cater to over 60 million patients in the country.
"We expect to launch few products to cater to diabetes patients in the next three years. It is expected that the number of patients will cross 100 million by 2030," he said.
However, even though diabetes is a main part of the company's portfolio, it has presence in osteoporosis, cardiovascular, oncology and growth hormones segments.